← Leaderboards
Teresa L. Wright
University Of California San Francisco
$3,215,991
Attributed
$3,215,991
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $233K · FY2005–09$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$3,215,991 · 6
By mechanism
R01$1,903,500 · 1
U19$1,090,744 · 2
P30$125,000 · 1
M01$96,747 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Paul R Harmatz$760,953
- Phyllis C Tien$21,664,639
- Leta Crawford-Miksza$970,549
- Karen S McCune$1,431,749
- Laura N Bull$7,328,977
Others in their field
Top investigators on “Hepatitis C”
- Constance Ann Benson · University Of California, San Diego$171,085,251
- Sharon A Nachman · Johns Hopkins University$116,441,543
- Peter B. Gilbert · Fred Hutchinson Cancer Center$94,107,997
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Richard Douglas Moore · Johns Hopkins University$59,121,971
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$46,122,050
Research focus
Hepatitis CHepatitis C VirusClinical ResearchHuman SubjectHiv InfectionsMicroorganism ImmunologyVirus LoadFibrosisPathologic ProcessLiver TransplantationLiverCytotoxic T LymphocyteComorbidityIntravenous Drug AbuseVirus RnaBiopsyNucleic Acid SequenceLiver DisorderProtein SequenceCaucasian AmericanHispanic AmericansImmunosuppressionCooperative StudyAfrican American
Grant awards (19)
Translational Core$224,511
U19 · FY2009 · AI · contact PI
Translational Core$217,971
U19 · FY2008 · AI · contact PI
Translational Core$215,722
U19 · FY2007 · AI · contact PI
Translational Core$217,766
U19 · FY2006 · AI · contact PI
Translational Core$214,774
U19 · FY2005 · AI
COMPLICATIONS OF INJECTION DRUG USE: HEPATITIS C$18,193
M01 · FY2005 · RR
HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS$412,500
R01 · FY2004 · DA
COMPLICATIONS OF INJECTION DRUG USE: HEPATITIS C$75,282
M01 · FY2004 · RR
COINFECTION WITH HEPATITIS C AND HIV$3,272
M01 · FY2004 · RR
HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS$372,750
R01 · FY2003 · DA
HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS$372,750
R01 · FY2002 · DA
IMMUNE PATHOGENESIS OF HEPATITIS C VIRUS--HUMAN MODEL$0
U19 · FY2002 · AI
HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS$372,750
R01 · FY2001 · DA
CORE--CLINICAL AND BIOSTATISTICS CORE$0
P30 · FY2001 · DK
IMMUNE PATHOGENESIS OF HEPATITIS C VIRUS--HUMAN MODEL$0
U19 · FY2001 · AI
HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS$372,750
R01 · FY2000 · DA
CORE--CLINICAL AND BIOSTATISTICS CORE$125,000
P30 · FY2000 · DK
IMMUNE PATHOGENESIS OF HEPATITIS C VIRUS--HUMAN MODEL$0
U19 · FY2000 · AI
IMMUNE PATHOGENESIS OF HEPATITIS C VIRUS--HUMAN MODEL$0
U19 · FY2000 · AI